Topic: antibiotics

Xenleta (lefamulin)

24. Xenleta

Xenleta is the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.

16. Recarbrio

While many Big Pharma companies have exited antibiotic R&D work, Merck is pressing along and this summer won FDA approval for Recarbrio to treat complicated urinary tract infections and complicated intra-abdominal infections.